0001209191-21-007560.txt : 20210203
0001209191-21-007560.hdr.sgml : 20210203
20210203200840
ACCESSION NUMBER: 0001209191-21-007560
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210201
FILED AS OF DATE: 20210203
DATE AS OF CHANGE: 20210203
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McAnear Justin J.
CENTRAL INDEX KEY: 0001786386
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39035
FILM NUMBER: 21588282
MAIL ADDRESS:
STREET 1: 10X GENOMICS, INC.
STREET 2: 6230 STONERIDGE MALL ROAD
CITY: PLEASANTON
STATE: CA
ZIP: 94588
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: 10x Genomics, Inc.
CENTRAL INDEX KEY: 0001770787
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 455614458
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6230 STONERIDGE MALL ROAD
CITY: PLEASANTON
STATE: CA
ZIP: 94588
BUSINESS PHONE: (925) 401-7300
MAIL ADDRESS:
STREET 1: 6230 STONERIDGE MALL ROAD
CITY: PLEASANTON
STATE: CA
ZIP: 94588
FORMER COMPANY:
FORMER CONFORMED NAME: 10X Genomics, Inc.
DATE OF NAME CHANGE: 20190315
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-01
0
0001770787
10x Genomics, Inc.
TXG
0001786386
McAnear Justin J.
C/O 10X GENOMICS, INC.
6230 STONERIDGE MALL ROAD
PLEASANTON
CA
94588
0
1
0
0
Chief Financial Officer
Class A Common Stock
2021-02-01
4
M
0
10000
5.04
A
30774
D
Class A Common Stock
2021-02-01
4
S
0
600
174.1817
D
30174
D
Class A Common Stock
2021-02-01
4
S
0
5213
175.5279
D
24961
D
Class A Common Stock
2021-02-01
4
S
0
2777
176.5109
D
22184
D
Class A Common Stock
2021-02-01
4
S
0
910
177.5002
D
21274
D
Class A Common Stock
2021-02-01
4
S
0
500
178.494
D
20774
D
Stock Option (right to buy)
5.04
2021-02-01
4
M
0
10000
0.00
D
2028-11-02
Class A Common Stock
10000
460159
D
The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
This transaction was executed in multiple trades at prices ranging from $173.50 to $174.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $175.00 to $175.96. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $176.02 to $177.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $177.03 to $177.93. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $178.11 to $178.98. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This option, originally for 600,000 shares, of which 139,841 shares have been exercised, vested as to one-fourth of the shares on October 8, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
/s/ Eric S. Whitaker, as Attorney-in-Fact
2021-02-03